You are here

  • Home
  • Archive
  • Volume 61, Issue Suppl 2
  • PMO-168 Effects of lidocaine 3% gel delivered rectally in anorectal dysfunction (ARD) induced by Telapravir therapy in chronic hepatitis C (CHC-C) a randomised placebo control study

Article info

Article menu

Download PDFPDF

Posters
Viral hepatitis
PMO-168 Effects of lidocaine 3% gel delivered rectally in anorectal dysfunction (ARD) induced by Telapravir therapy in chronic hepatitis C (CHC-C) a randomised placebo control study
Free

Authors

Citation

Basu P, Nair T, Farhat S, et al
PMO-168 Effects of lidocaine 3% gel delivered rectally in anorectal dysfunction (ARD) induced by Telapravir therapy in chronic hepatitis C (CHC-C) a randomised placebo control study
Gut 2012;61:A142.

Publication history

  • First published May 28, 2012.
Online issue publication 
April 18, 2016

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© 2012, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.